tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

EKF Diagnostics Reports Record Sales and Strong Financial Performance in H1 2025

Story Highlights
EKF Diagnostics Reports Record Sales and Strong Financial Performance in H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from EKF Diagnostics Holdings ( (GB:EKF) ).

EKF Diagnostics Holdings plc reported record analyzer sales and improved earnings for the first half of 2025, with gross margins rising to 50.2% and a 16.1% increase in pre-tax profit. The company is on track to meet full-year revenue and adjusted EBITDA growth expectations, supported by strong performances in Hematology and β-HB product lines. The strategic development plan is yielding results, with increased production capacity and a focus on high-margin products driving profitability. The company also completed a share buyback and canceled a loan facility due to strong cash generation, indicating a robust financial position.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on GB:EKF Stock

According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.

EKF Diagnostics Holdings has a solid financial foundation with strong profit margins and low leverage, which are the most significant factors in its score. The technical analysis shows a positive trend, although momentum is not strong. The valuation is moderate, with a P/E ratio suggesting fair pricing, but the lack of a dividend yield is a downside for income investors.

To see Spark’s full report on GB:EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings plc is an AIM-listed global diagnostics business focused on Point-of-Care analyzers, particularly in Hematology and Diabetes, and Life Sciences, offering contract fermentation services for clinically important enzymes and proteins. The company manufactures Beta-Hydroxybutyrate (β-HB) for use in quantitative ketone testing and other clinical applications. Headquartered in Penarth, near Cardiff, EKF operates five manufacturing sites across the US and Germany, selling products in over 120 countries worldwide.

Average Trading Volume: 295,695

Technical Sentiment Signal: Hold

Current Market Cap: £131.6M

For detailed information about EKF stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1